Tesamorelin price in 2026: Egrifta WR and research-grade vials

What is published about Egrifta WR pricing, set apart from what US suppliers list for research-grade tesamorelin per vial and per mg, as checked on November 17, 2026.

Buying guide7 min read

Key takeaway

Egrifta WR is a prescription medicine, and Theratechnologies did not publish a list price on any manufacturer page we could load on November 17, 2026. Research-grade tesamorelin is a laboratory reagent: US suppliers listed 10 mg vials at $35.00 to $120.00, or $3.50 to $12.00 per mg. Vitrapep lists a 5 mg vial at $69.99, for laboratory research use only, not for human or veterinary use.

At a glance

Article typeBuying guide
Main guideTesamorelin: complete guide
Regulatory statusFDA-approved“Tesamorelin is FDA-approved” (Tesamorelin: complete guide)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism, Brain & nervous system
Studies cited2 in this article · 24 across 11 articles on Tesamorelin
ProductTesamorelin product page

Tesamorelin price searches lead to two very different products. Egrifta WR is an FDA-approved prescription medicine made by Theratechnologies. Research-grade tesamorelin is a lyophilized peptide sold for laboratory research use only. They sit in different regulatory categories, and their prices are set in different ways. This page covers what is published for each as of November 17, 2026, and what US research suppliers listed that day.

Quick answer: There is no manufacturer list price for Egrifta WR on the Theratechnologies pages we could reach. Research-grade tesamorelin, a different product category, listed at $35.00–$120.00 per 10 mg vial at the US suppliers we checked on November 17, 2026. Vitrapep lists 5 mg at $69.99.

Two products, two categories

Tesamorelin is a synthetic analog of human growth hormone-releasing factor. It is made of the 44-amino-acid sequence of human GRF with a hexenoyl group attached to the tyrosine at the N-terminal end, and it is prepared as an acetate salt (DailyMed, 2025). It was studied in people with HIV in a randomized trial published in 2007 (Falutz et al., 2007). Our tesamorelin research guide covers that history.

  • Prescription medicine. Egrifta WR is FDA-approved, manufactured under drug rules and dispensed by a pharmacy on a prescription. Its price depends on the pharmacy, the insurance plan and any manufacturer program.
  • Research reagent. Research-grade tesamorelin is a lyophilized powder sold for laboratory work. FDA has not reviewed it as a drug. It is for laboratory research use only, not for human or veterinary use.

One is not a substitute for the other. The prices in this article describe two separate markets, not a choice between them. Our explainer on research use only labeling covers what that label means.

Egrifta WR: approval and published cost

The tesamorelin biologics license, BLA 022505, was first approved on November 10, 2010, for the original Egrifta product (FDA, Drugs@FDA). FDA records show a supplement to that license approved on March 25, 2025 (openFDA), and the Egrifta WR label carries a revision date of March 2025. The label states that Egrifta WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and that it is not indicated for weight management (DailyMed, 2025).

On price, the public record is thin:

  • No published list price. We found no list price or wholesale acquisition cost for Egrifta WR on any Theratechnologies page we could load on November 17, 2026.
  • Third-party figures vary widely. Discount-card and pharmacy sites quote numbers that differ by several times. They are not manufacturer sources, so we do not repeat them here.
  • What a person pays for a prescription medicine depends on the dispensing pharmacy, insurance coverage and any manufacturer support program. Those terms come from the pharmacy and the manufacturer, not from a research supplier.

Research-grade tesamorelin prices at US suppliers

We checked supplier product pages on November 17, 2026, and recorded the listed single-vial price. Prices exclude shipping, codes and pack discounts.

Table 1

Research-grade tesamorelin prices at US suppliers, checked November 17, 2026

Supplier Vial size Listed price Price per mg
MyPurePeptide10 mg$35.00$3.50
MyPurePeptide20 mg$75.00$3.75
Purgo Labs (listed as “Tesamorlin”)10 mg$69.99$7.00
Core Peptides5 mg$43.00$8.60
Core Peptides10 mg$79.00$7.90
Zeptix Labs10 mg$99.99$10.00
American Peptides (listed as AP-TESA, code TH9507)10 mg$120.00$12.00
Vitrapep5 mg$69.99$14.00

Sources: supplier product pages listed in the references, read November 17, 2026. Price per mg is the listed price divided by the vial size. MyPurePeptide showed a struck-through price of $40.00 on its 10 mg vial, and Zeptix Labs showed $129.99 struck through on its 10 mg vial and was running a buy-one-get-one offer. Purgo Labs offered $52.49 with a first-order code. Core Peptides shows a $43.00–$79.00 range; the per-size prices come from its discount table. The American Peptides page does not use the name tesamorelin.

Two things stand out. The spread is wide: 10 mg vials ran from $35.00 to $120.00, more than a threefold gap for the same labeled amount. And Vitrapep’s price per mg is the highest in the table, because it sells a 5 mg vial only, and small vials carry more fixed cost per mg.

What drives the tesamorelin price spread

Our peptide prices explainer covers these levers across the catalog. For tesamorelin they work like this:

  • Length. At 44 residues, tesamorelin is long for a research peptide. Solid-phase synthesis adds one amino acid at a time, and every coupling step loses some yield, so long chains cost more per mg (Verlander, 2007).
  • The N-terminal modification. The hexenoyl group is what distinguishes tesamorelin from the unmodified GRF sequence. Adding it is an extra chemical step with its own purification.
  • Purity and outside testing. HPLC purity and mass spectrometry identity from an outside laboratory, tied to the specific lot, are a real cost per batch. Laboratories accredited to ISO/IEC 17025 have been assessed for testing competence.
  • Vial size. Filling, sealing, labeling and lot testing cost about the same for a 5 mg or a 20 mg vial, so larger vials cost less per mg.
  • Promotions. Struck-through prices, buy-one-get-one offers and first-order codes move the effective price from week to week.

What to check before trusting a low price

  • The compound name. If the product page and the certificate do not name tesamorelin, or misspell it, identity cannot be checked against the label.
  • A lot-specific certificate. It should name the lot, the testing laboratory, the test date, HPLC purity and a mass spectrometry result that matches tesamorelin’s molecular weight of 5,135.9 Da as the free base (DailyMed, 2025). Our guide to reading a certificate of analysis walks through each field.
  • Prices far below the rest. A low price is not proof of a problem, but it leaves less room for outside testing on every lot.
  • Human-use language. A research listing should carry no dosing or human-use instructions. Its label should say research use only.

What Vitrapep charges for tesamorelin

Vitrapep lists tesamorelin as a 5 mg lyophilized vial at $69.99, or $14.00 per mg. Store prices may still change before launch. The product page lists the sequence, molecular formula and how to look up each lot’s test report. It is a research reagent, sold for laboratory research use only and not for human or veterinary use. It is not Egrifta WR and not a substitute for any prescription medicine. For sourcing questions, see where to buy tesamorelin.

Tesamorelin

Lyophilized Lot documentation Research use only

Specifications and the current lot’s test documentation for the tesamorelin sold for laboratory research.

View tesamorelin specifications

Frequently asked questions about tesamorelin price

How much does tesamorelin cost?

It depends on the product. Egrifta WR, the prescription medicine, had no manufacturer list price on the pages we could load on November 17, 2026. Research-grade tesamorelin listed at $35.00 to $120.00 per 10 mg vial at the US suppliers we checked, or $3.50 to $12.00 per mg.

What is Egrifta WR approved for?

Its label states that it is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and that it is not indicated for weight management (DailyMed, 2025).

Is research-grade tesamorelin the same as Egrifta WR?

No. Egrifta WR is an FDA-approved prescription medicine, manufactured and tested under drug rules and dispensed by a pharmacy. Research-grade tesamorelin is a laboratory reagent that FDA has not reviewed as a drug. It is for laboratory research use only, not for human or veterinary use, and it is not a substitute for any prescription medicine.

Why does tesamorelin cost more than many short peptides?

It is 44 amino acids long and carries an N-terminal hexenoyl modification. Longer sequences take more synthesis steps and more purification, and the modification adds a step. Both raise the cost per mg.

Why is a 5 mg vial more expensive per mg than a 10 mg vial?

Filling, sealing, labeling and lot testing cost about the same regardless of vial size. In a smaller vial, those costs are spread over fewer milligrams. Core Peptides, for example, listed $8.60 per mg at 5 mg and $7.90 per mg at 10 mg on November 17, 2026.

What to know now

  • Egrifta WR is a prescription medicine. Its license dates to November 10, 2010, and its label was revised in March 2025.
  • No published list price. No Theratechnologies page we could load on November 17, 2026, showed one.
  • Research-grade 10 mg vials listed at $35.00–$120.00. That is $3.50 to $12.00 per mg across the US suppliers we checked.
  • Vitrapep lists 5 mg at $69.99. At $14.00 per mg, it is the highest per-mg price in our table.
  • Check identity before price. A named compound and a lot-specific certificate matter more than a discount.

What we’re watching

First, whether Theratechnologies publishes pricing for Egrifta WR on its product site once it loads again. Second, the wide spread in research-grade listings, where 10 mg vials ranged more than threefold on the same day. Third, naming practices, since several listings use codes or misspellings instead of the compound name. We will re-check these prices as they change.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Theratechnologies Inc 2025, EGRIFTA WR (tesamorelin) kit: Prescribing information; U.S. Food and Drug Administration. (n.d.). Drugs@FDA: BLA 022505 (Egrifta) . Retrieved November 17, Drugs@FDA: BLA 022505 (Egrifta); U.S. Food and Drug Administration. (n.d.). openFDA Drugs@FDA record for BLA022505 (supplement approved March 25, openFDA Drugs@FDA record for BLA022505; Falutz 2007, New England Journal of Medicine; Verlander 2007, International Journal of Peptide Research and Therapeutics; International Organization for Standardization 2017; MyPurePeptide. (n.d.). Tesamorelin 10mg and Tesamorelin 20 mg [Product pages]. Retrieved November 17, Tesamorelin 10mg; Purgo Labs. (n.d.). Tesamorlin [Product page]. Retrieved November 17, Tesamorlin; Core Peptides. (n.d.). Tesamorelin: 5MG / 10MG [Product page]. Retrieved November 17, Tesamorelin: 5MG / 10MG; Zeptix Labs. (n.d.). Tesamorelin [Product page]. Retrieved November 17, Tesamorelin; American Peptides. (n.d.). AP-TESA (TH9507) [Product page]. Retrieved November 17, AP-TESA (TH9507). All 11 citations

Back to the research library

References

  1. Theratechnologies Inc. (2025). EGRIFTA WR (tesamorelin) kit: Prescribing information (Revised 3/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: BLA 022505 (Egrifta). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
  3. U.S. Food and Drug Administration. (n.d.). openFDA Drugs@FDA record for BLA022505 (supplement approved March 25, 2025). Retrieved November 17, 2026, from https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA022505
  4. Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
  5. Verlander, M. (2007). Industrial applications of solid-phase peptide synthesis: A status report. International Journal of Peptide Research and Therapeutics, 13(1–2), 75–82. https://doi.org/10.1007/s10989-006-9075-7
  6. International Organization for Standardization. (2017). ISO/IEC 17025:2017: General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
  7. MyPurePeptide. (n.d.). Tesamorelin 10mg and Tesamorelin 20 mg [Product pages]. Retrieved November 17, 2026, from https://mypurepeptide.com/product/tesamorelin-10-mg/ and https://mypurepeptide.com/product/tesamorelin-20-mg/
  8. Purgo Labs. (n.d.). Tesamorlin [Product page]. Retrieved November 17, 2026, from https://purgolabs.com/products/tesamorlin
  9. Core Peptides. (n.d.). Tesamorelin: 5MG / 10MG [Product page]. Retrieved November 17, 2026, from https://www.corepeptides.com/peptides/tesamorelin-10mg/
  10. Zeptix Labs. (n.d.). Tesamorelin [Product page]. Retrieved November 17, 2026, from https://zeptixlabs.com/product/tesamorelin/
  11. American Peptides. (n.d.). AP-TESA (TH9507) [Product page]. Retrieved November 17, 2026, from https://americanpeptides.us/products/ap-tesa